The Phase 2a 12-week, multicenter, randomized, double-blind, placebo-controlled, parallel group trial
for PXL770 was initiated in April 2019.
Among those trials, 782 were randomized, parallel group trial
followed by 623 of single arm trial.
The first is a randomized, double-blind, placebo-controlled, parallel group trial
. The second is an open-label, long-term safety trial.
The clinical trial, known as the Optimizing Protein Intake in Older Men (OPTIMen) Trial, was a randomised, placebo-controlled, double-blind, parallel group trial
in which men aged 65 or older were randomized to receive a diet containing 0.8-g/kg/day protein and a placebo injection; 1.3-g/kg/day protein and a placebo injection; 0.8-g/kg/day protein and a weekly injection of testosterone; or 1.3-g/kg/day protein and a weekly injection of testosterone.
The first stage of the trial is a double-blind, controlled, parallel group trial
where 600 adult patients will be randomized to receive up to 28 days of transfusion support with INTERCEPT-treated RBCs or conventional RBCs, with a primary endpoint of hemoglobin increment following transfusion.
According to the company, the global, multi-centre, randomised and double-blind placebo-controlled parallel group trial
achieved its primary endpoint and all secondary endpoints with statistically significant and clinically meaningful results for all three lanadelumab treatment arms compared to placebo.
Data source: The findings are based on a 5-year, open-label, multicenter, randomized parallel group trial
with 2,418 infants, ages 3-12 months, receiving either pimecrolimus 1% cream or topical corticosteroids for treatment of atopic dermatitis.
Cervical preparation with 400 mcg of misoprostol significantly reduced complications in women undergoing first-trimester abortion by vacuum aspiration, based on data from a randomized, parallel group trial
of nearly 5,000 women.
RESEARCH DESIGN AND METHODS: Trial 1 was a randomized, prospective, double-blind, placebo-controlled, parallel group trial
in atopic subjects with mild-to-moderate asthma (n = 35 evaluable) consuming a low dose (0.75 g GLA + 0.5 g EPA), high dose (1.13 g GLA + 0.75 g EPA) or placebo emulsion daily.
DAR-311 is an international Phase 111 double-blind, placebo-controlled parallel group trial
, in which 379 patients were randomized to receive once-daily doses of darusentan 50 or placebo for up to 14 weeks as an add-on to existing antihypertensive regimens.
The 4-arm, parallel group trial
will enroll 200 patients and compare 0.25 mg, 0.5 mg and 1.0 mg once daily oral doses of CH-1504 to a 20 mg once weekly oral dose of MTX.
Health costs and quality of life data have yet to be presented from the three-arm, randomized, parallel group trial
of 453 patients managed in U.K.